anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

212,041-212,100 of 319,975

filter-aware
28
Bigbear AI | Investor Presentation Deck | 29 slidesBigbear AI | Investor Presentation Deck | 29 slides · BigBear.ai
Pitch deck Investor relations 1 hit
29
Bigbear AI | Investor Presentation Deck | 29 slidesBigbear AI | Investor Presentation Deck | 29 slides · BigBear.ai
Pitch deck Investor relations 1 hit
01
Slide 1
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
02
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
03
The slide uses a linked-circle diagram to represent the interconnected nature of the company's value proposition.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
The slide uses a grid layout to display 8 team members with headshots, names, titles, and logos of past companies.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses a visual comparison between healthy cells (alkaline) and cancer cells (acidic) to demonstrate the selective binding mechanism.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a three-column layout to categorize the platform's application, each with a corresponding antibody diagram.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a horizontal bar chart integrated into a table to represent clinical trial phases.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
09
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
10
The slide uses a structured list format to define the target market and unmet medical need.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
11
The slide uses a waterfall plot for response and a spider plot for longitudinal tumor burden change.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
12
Includes a spider plot for target lesion change and a Kaplan-Meier survival curve with a summary table.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
13
Includes clinical trial design details (dosing regimens, patient counts, endpoints).BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
14
The slide uses a decision tree/process flow to map patient cohorts to clinical outcomes and subsequent trial progression.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
15
Includes specific clinical trial data (N=73 and N=26) and detailed breakdown of specific adverse events like constipation, neuropathy, and diarrhea.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
16
Includes detailed footnotes for data sources and medical abbreviations.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
17
The chart is a classic waterfall plot used in oncology to show tumor shrinkage/growth.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Traction1 hit
18
The slide uses a process-oriented layout to describe clinical trial progression.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Traction1 hit
19
Data cut-off Jan 4, 2023. Includes partial and complete responses.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Traction1 hit
20
Includes waterfall plot (left) and spider plot (right) for patient response data.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
21
Includes specific clinical trial safety metrics and footnotes regarding data definitions.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
22
The table displays specific drug administration schedules (mg/kg) for different cycle lengths and days.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
23
Includes abbreviations for indications (LMS, UPS, NSCLC) and trial design details.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
24
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
25
The slide uses a combination of high-level market statistics and specific clinical benchmarks to define the target opportunity.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
26
The chart highlights a specific patient case with a partial response (PR) and notes a suboptimal dose case.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
27
Uses a 2x2 grid of metrics to frame the problem space.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
28
The chart tracks % change in target lesions over time (weeks) for two specific patients.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
29
The slide uses a funnel-like logic to narrow down from total prevalence to a specific addressable patient population for a 2L+ therapy.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
30
The slide uses a table to present clinical trial outcomes (PR/CR) and safety data.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
31
The slide outlines patient enrollment targets and treatment protocols for specific refractory patient populations.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
32
The table compares dosing schedules for a clinical trial drug.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
33
BA3021 Ozuriftamab VedotinBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
34
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
35
The slide uses a combination of a summary table for clinical endpoints and a dot plot for NHP toxicity data.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
36
The slide outlines a dose-escalation study (3+3 design) leading to RP2D selection and subsequent expansion cohorts.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
37
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
38
The slide uses a before-after-bridge style comparison between the problem (toxicity) and the solution (BA3182).BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
39
The slide uses a process flow diagram to illustrate dose escalation strategies (Accelerated vs Standard vs Priming).BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
40
The slide uses a two-column layout to represent 1H and 2H of 2023.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
41
The slide uses a linked-circle diagram to represent the interconnected nature of their technology, pipeline, and financial health.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations 1 hit
42
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations 1 hit
43
The chart uses a log scale for the Y-axis. The legend defines the three regimens: Q2W, 2Q3W, and 3Q4W.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations 1 hit
01
Slide 1
Blue Apron | Investor Presentation Deck | 23 slidesBlue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations 1 hit
02
Includes specific financial figures related to the FreshRealm transaction and capital raises.Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations 1 hit
03
Blue Apron | Investor Presentation Deck | 23 slidesBlue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations 1 hit
04
Blue Apron | Investor Presentation Deck | 23 slidesBlue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Beat · Team1 hit
05
The slide uses a central white box overlay on a split-image background (food scene and delivery scene).Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations 1 hit
06
Blue Apron | Investor Presentation Deck | 23 slidesBlue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations 1 hit
07
The slide uses a strong visual of the product to establish brand identity.Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Beat · Solution1 hit
08
Blue Apron | Investor Presentation Deck | 23 slidesBlue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Beat · SolutionLoop · Mece Breakdown1 hit
09
Blue Apron | Investor Presentation Deck | 23 slidesBlue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Beat · Business ModelLoop · Mece Breakdown1 hit
10
The slide highlights both year-over-year and quarter-over-quarter margin growth.Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations 1 hit
11
The slide uses a background image of food/wine, likely related to the company's industry.Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations 1 hit
12
The slide uses a background of sliced tomatoes, likely a brand-related visual element for Blue Apron.Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Loop · Voice Of Customer1 hit
13
Includes YoY growth percentages for each metric per quarter.Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Loop · Voice Of Customer1 hit
14
Includes specific financial targets related to rebates, cash consideration, and seller notes.Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations 1 hit
15
The EBITDA loss range is presented as $27-23 million, which is counter-intuitive ordering (high to low).Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit